Xenetic to advance DNase programme with UVA partnership

18 Jan 2024
www.pharmaceutical-technology.com
License out/inImmunotherapyClinical Study
Xenetic to advance DNase programme with UVA partnership
Preview
Source: Pharmaceutical Technology
Under the agreement, the parties will develop Xenetic’s DNase-based platform. Credit: Maksim Shmeljov/Shutterstock.com.
Xenetic Biosciences has entered into research funding and material transfer agreements with the University of Virginia (UVA) in the US to advance its systemic deoxyribonuclease (DNase) programme.
The parties will develop Xenetic’s DNase-based oncology platform.
The platform acts on neutrophil extracellular traps (NETs), weblike structures that comprise extracellular chromatin covered with histones and other proteins.
The new initiative addresses NETs associated with inflammatory and autoimmune diseases, as well as cancer progression.
Excessive levels of NETs can create pro-tumorigenic niches that may limit the effectiveness of cancer therapies.
The platform is designed to complement existing cancer treatments including immunotherapies.
The agreements grant Xenetic an option to solely license any new intellectual property resulting from the DNase research programme. This is in addition to advancing the existing intellectual property of Xenetic.
Xenetic scientific advisory board member and UVA School of Medicine Department of Surgery chair Allan Tsung will oversee the research.
The company is preparing for a first-in-human clinical trial to assess DNase plus immune checkpoint inhibitors or chemotherapy.
Xenetic CEO Jeffrey Eisenberg stated: “We believe the data generated by our research and development collaborations are key to fully unlocking the potential of our DNase technology and importantly, providing translational insights as we drive a clinical path for our lead solid tumour indications.
“These agreements provide a significant addition to our development capabilities and resources, and we believe it bolsters our opportunity to accelerate development timelines.
“Additionally, we are pleased to deepen our work with Dr Tsung, who has provided a valuable perspective to our team and significant insight for our DNase platform.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.